Thymogen
Thymogen is a synthetic dipeptide (Glu-Trp) developed as a simplified thymic-factor analog, studied almost exclusively in Russian animal research for immune-modulating, antioxidant, and hepatoprotective effects, with essentially no independently replicated human clinical trial data.
This page is a research-orientation summary, not a dosing guide. For anything beyond general background, read the primary literature or talk to a qualified clinician — specifics like amount, frequency, or administration aren't something we publish here.
What it does & how it works
Thymogen (L-glutamyl-L-tryptophan) is proposed to influence T-lymphocyte differentiation and general immune cell activity, echoing the immunostimulatory role attributed to natural thymic peptide factors. Its biological activity appears stereospecific: the enantiomer D-Glu-D-Trp (marketed as Thymodepressin) has the opposite, immunosuppressive effect, which researchers use as evidence that the molecule's activity depends on specific chiral interactions rather than nonspecific effects. Separately, in liver-injury models Thymogen and its structural analogues are reported to reduce oxidative stress (lower lipid peroxidation, restored catalase activity) and support hepatocyte regeneration, though the receptor(s) mediating this antioxidant/hepatoprotective action are not well defined in the available literature.
Typical results seen in research
Available effects data are limited to rodent studies from a small number of Russian laboratories. In rat models of hydrazine- and carbon-tetrachloride-induced liver injury, Thymogen and its D-alanine-modified analogues reduced markers of oxidative stress and promoted hepatocyte regeneration, with C-terminal-modified analogues outperforming native Thymogen. No human clinical trial data evaluating Thymogen's immune or hepatoprotective effects were identified in PubMed.
How it’s commonly used
In published animal research, Thymogen has been administered via intraperitoneal or intragastric routes. Manufacturer and clinical-practice literature in Russia describes intramuscular or intranasal administration for immune support, but this usage is not corroborated by PubMed-indexed controlled human trials.
- Bulletin of Experimental Biology and Medicine · 2025 Hepatoprotective Effects of Thymogen Analogues in Hydrazine Hepatopathy in Rats
- Bulletin of Experimental Biology and Medicine · 2023 Reparative and Antioxidant Effects of New Analogues of Immunomodulator Thymogen in Experimental Model of Liver Damage
- International Journal of Molecular Sciences · 2024 The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples
Curated from published literature for research orientation. Not an exhaustive review, and not a substitute for reading primary sources.